Patients with confirmed progressive disease following the first-line treatment with a gemcitabine-based regimen were randomised to receive either S-@ ( @/@/@mgday ( -@ ) based on body surface area ( BSA ) , orally , days @-@ , every @ weeks ) or SOX ( S-@ @/@/@mgday ( -@ ) based on BSA , orally , days @-@ , plus oxaliplatin @mgm ( -@ ) , intravenously , day @ , every @ weeks ) .